St Paul, MN (PRWEB) August 01, 2012
MD Biosciences, a preclinical CRO, in collaboration with Fraunhofer IGB announces a revolutionary, in vitro preclnical 3D human skin equivalent (HSE) system. The model enables scientists to measure the penetration, resorption, metabolism and epidermal impedance in a human skin equivalent system. Penetration across the layers is visible, enabling the determination of intracellular drug transport. The system offers two uptake routes for drugs:
Additionally, the HSE system can be vascularized using BioVaSc technology:
About MD Biosciences
MD Biosciences is a Preclinical and Clinical Contract Research Organization (CRO) providing services for biotech/pharmaceutical, medical device and animal health. Our core therapeutic focus is in inflammation/autoimmune, neurology/CNS disorders, pain and cardiovascular as well as the interplay between the inflammatory, neurology and cardiovascular systems. Our approach is to work backwards from the clinic, understanding what the clinicians would expect from an active compound. This approach and understanding enables the development of models and biomarkers that help break the preclinical/clinical barrier and provide more clinically relevant data at earlier stages.
About Fraunhofer IGB
Fraunhofer IGB develops and optimizes processes and products in the fields of medicine, pharmacy, chemistry, the environment and energy. Fraunhofer combines the highest scientific quality with professional expertise in fields of competence always with a view to economic efficiency and sustainability. Fraunhofer IGB is one of more than 80 research units of the Fraunhofer-Gesellschaft, Europe’s largest non-profit organization for application-oriented research. Fraunhofer IGB has obtained a patent for the three-dimensional human skin equivalent (patent ID: EP 1 290 145 B1) and in 2009 developed the biological vascularized matrix (BioVaSc) winning a technology prize for “human-centered” technology by the Fraunhofer-Gesellschaft.
The information in this press release should be considered accurate only as of the date of the release. MDB has no intention of updating and specifically disclaims any duty to update the information in these press releases.